Single-Arm, Open-Label Phase II Efficacy Study of First-in-Class HIF2-Alpha Inhibitor, PT2385, for Patients With Recurrent Glioblastoma

Trial Profile

Single-Arm, Open-Label Phase II Efficacy Study of First-in-Class HIF2-Alpha Inhibitor, PT2385, for Patients With Recurrent Glioblastoma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 21 May 2018

At a glance

  • Drugs PT 2385 (Primary)
  • Indications Glioblastoma
  • Focus Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 11 May 2018 Planned primary completion date changed from 31 May 2018 to 31 Dec 2018.
    • 11 May 2018 Status changed from recruiting to active, no longer recruiting.
    • 15 Aug 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top